Charles Huiner will start immediately and lead the Company’s Series C fundraising and execution of a focused growth strategy for its FDA-cleared product, Clarifi®.
Charles Huiner brings over 25 years of executive experience with a successful leadership track record across multiple life science market segments including biotech, medical devices, and digital health. Most recently, he served as Chief Operating Officer and Senior Vice President, Corporate Development and Strategy for Sientra, Inc. (NASDAQ: SIEN), a global medical aesthetics company with annual revenues exceeding $80 million.
While serving at Sientra, Charles Huiner authored the company’s growth strategy, led several key acquisitions, and helped execute $375 million in equity financing including a successful IPO. Prior to that, he was Vice President of Marketing and Business Development at InTouch Health during a transformative period that solidified the company’s market strategy and commercial model, leading to its eventual $600 million exit to Teladoc Health. Previously, as Senior Director of Corporate Development and Strategy at INAMED, Inc. he was instrumental in broadening the company’s product portfolio that contributed to its $3.3 billion acquisition by Allergan Aesthetics.
“It’s fantastic to have Charlie on-board to lead Modulim’s next phase,” said David Cuccia, Modulim’s Founder, Board member and Chief Technology Officer. “With Charlie’s experience and expertise, we are poised to build from a number of key milestones recently achieved by the Company to accelerate commercialization. The whole executive team looks forward to working with him to enact Modulim’s mission—to deliver transformative optical solutions that help people live healthier, longer lives.”
“I am excited for the opportunity to lead Modulim’s talented team. The Company will play a significant role in the ongoing convergence of medical diagnostic, predictive AI, and telehealth technologies to enable more efficient healthcare delivery. Our decision support solutions are applicable to numerous ill-met chronic conditions and vascular complications, starting with helping healthcare providers prevent costly and often deadly undiagnosed conditions brought on by diabetes and peripheral arterial disease,” said Huiner. “I look forward to working with my new colleagues to accelerate the adoption and expansion of our proprietary SFDI technology while improving the lives of patients.”
“We are pleased to have attracted a high-caliber, proven executive like Charlie to strengthen the Company and advance on early successes with strategic customers,” said Janelle Goulard, Partner at Pangaea Ventures. “Charlie brings extensive technology commercialization knowledge and experience at this dynamic period of growth for Modulim. We believe the Clarifi solution will positively impact millions that are living with chronic conditions.”